Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19565943 | 1.00 | NFKB1 (0.31) | NFKB1NFKB2RELA | |
| SCHEMBL19566003 | 1.00 | NFKB1 (0.31) | NFKB1NFKB2RELA | |
| SCHEMBL19566004 | 1.00 | NFKB1 (0.31) | NFKB1NFKB2RELA | |
| SCHEMBL19565938 | 0.85 | — | — | |
| SCHEMBL19565864 | 0.85 | — | — | |
| SCHEMBL19552528 | 0.74 | KMT2A (0.30) | — | |
| SCHEMBL19548856 | 0.73 | KMT2A (0.35) | — | |
| SCHEMBL19548535 | 0.73 | KMT2A (0.35) | — | |
| SCHEMBL19548770 | 0.73 | KMT2A (0.35) | — | |
| SCHEMBL19548655 | 0.73 | KMT2A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | Oncoarendi Therapeutics S.A. (PL) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | ARG1, ARG2, ARGLU1 | NFKB1 1570/4885NFKB2 1372/4885RELA 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.